Seeking Alpha

Sanofi-Aventis (SNY -2%) settles more patent infringement suits over its cancer drug Eloxatin,...

Sanofi-Aventis (SNY -2%) settles more patent infringement suits over its cancer drug Eloxatin, this time with Mayne Pharma (HSP), Par Pharmaceutical (PRX) and Iceland's Actavis. The firms will stop selling unauthorized versions of Eloxatin in the U.S. between June 30, 2010 and Aug. 9, 2012, which should boost Sanofi's sales.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs